其中部分原因是阿斯特捷利康公司在20年前就进入了中国市场。
This is partly due to AstraZeneca’s sales push into China a decade ago.
那么，如果不通过对手们所热衷的合并，他计划如何拯救阿斯特捷利康呢？
So how does he plan to save AstraZeneca, if not through the merger mania now intoxicating his rivals?
在去年英国基准指标富时100指数股票中，阿斯特捷利康是表现最好的股票之一。
Its shares were among the best-performing in Britain's benchmark FTSE 100 index last year.
应用推荐